The life sciences sector is growing in Canada and AbbVie is honoured to contribute to Canada’s thriving scientific research and innovation community. As a leading global research-based pharmaceutical company, and one of the largest biopharmaceutical organizations in Canada, our Montreal and Markham offices teams along with our colleagues across Canada are dedicated to developing and delivering medicines that address both current and future health challenges. We focus on key therapeutic areas—including immunology, oncology, neuroscience, eye care, virology, gastroenterology and aesthetics—where our expertise allows us to support improvements in disease management.
AbbVie’s commitment extends to Canada’s life sciences ecosystem through investments in education, innovation and collaboration. In 2024, we introduced the AbbVie Biotech Innovators Award, collaborating with SpinUp, the University of Toronto’s life sciences accelerator. The award offers the early-stage biotech recipient with a year of laboratory space, mentorship, and access to essential research resources.
In 2022, AbbVie played a key role in establishing the AbbVie Chair of Ethnodermatology at the University of Toronto’s Temerty Faculty of Medicine through a significant contribution. This position is notable for being among the first of its kind globally and underscores AbbVie’s commitment to promoting diversity and advancing research excellence in dermatology.
From drug discovery to clinical trials, AbbVie is pursuing new ways to address patients’ most challenging health issues. Through significant investments in clinical research, AbbVie has established 586 Canadian trial sites that have enrolled nearly 5,800 patients. Strategic collaborations with AbCellera, to leverage its antibody discovery and development platform, and with Ripple, to leverage its innovative drug delivery platform to develop next-generation therapies for glaucoma management, further exemplify AbbVie’s commitment to collaboration and innovation.
Through a long-standing partnership with Crohn’s and Colitis Canada, AbbVie empowers people living with Crohn’s disease and ulcerative colitis with an annual scholarship program. Since 2012, more than 180 post-secondary students have been awarded bursaries, encouraging them to take charge of their health while easing the financial burden so they can focus on their studies and future success.
“At AbbVie, we value our role in strengthening Canada’s position as a global leader in life sciences. We recognize the significant potential within Canadian research and healthcare and remain dedicated to ongoing collaboration and discovery for the benefit of patients,” Rami Fayed, Vice President and General Manager, AbbVie, Canada.
We care about making a lasting, meaningful difference for Canadians—today and for future generations—through our pursuit of scientific breakthroughs and the collaborative approaches we take to achieve them.
